Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435334 | 0.86 | HSD11B1 (0.71) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL10695332 | 0.84 | HSD11B1 (0.73) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL435013 | 0.80 | HSD11B1 (0.68) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL1807144 | 0.79 | HSD11B1 (0.54) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL1806218 | 0.76 | HSD11B1 (0.54) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL31650200 | 0.76 | ALDH1A1 (0.38) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL16232162 | 0.75 | HSD11B1 (0.60) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL12002387 | 0.75 | SLC6A3 (0.62) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL435866 | 0.74 | SLC6A3 (0.67) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL17761297 | 0.74 | HSD11B1 (0.73) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102686571-B | tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-102686571-A | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | HSD11B1 782/4885SLC6A3 3263/4885CACNA1G 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.